Cantor Fitzgerald analyst Kristen Kluska assumed coverage of PolarityTE and kept an Overweight rating on the shares with a price target of $13, down from the firm's prior target to $50. The stock closed Friday up 32c to $3.31. Kluska lowered the company's peak revenue estimate to $500M from $1.2B in 2032. Expectations are now lower for SkinTE, and as a result, the setup for shares is better for quarterly revenues over the next 12 months, Kluska tells investors in a research note titled "A Current Valuation That Truly Gets Under the Skin." She believes clinical data from three trials next year, head-to-head burn, diabetic foot ulcers and venous leg ulcers, should be positive and could lead to increased awareness and adoption in near term.